A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Combination With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
Conditions: Renal Carcinoma; Renal Cell Carcinoma; Urothelial Carcinoma Interventions: Biological: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells; Biological: N-803 Sponsors: Dana-Farber Cancer Institute; Kidney Cancer Association; ImmunityBio, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Research | Study | Urology & Nephrology